Bank believes in cancer approval for Genmab
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
by marketwire, translated by daniel pedersen
Danish bank Jyske Bank has changed its investor recommendation for biotech company Genmab due to the recent year’s stock hike of more than 20% despite a downturn of the underlying market.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab has two potential blockbusters up its sleeve
For subscribers
Analyst spots strong figures behind Genmab upgrade
For subscribers
